Department of the Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology

• Drug antitumor treatment of tumors of undetected primary localization (unknown primary origin treatment);
• Drug antitumor treatment of cancer patients who are on hemodialysis or with concomitant renal insufficiency, as well as patients with nephrostomy and stenting of the ureters;
• Drug antitumor treatment of kidney cancer, bladder, pelvis, prostate, penis, testicles;
• Drug antitumor treatment of ovarian cancer, uterine body, cervical cancer;
• Drug antitumor treatment of breast cancer;
• Drug antitumor treatment of stomach, pancreatic, liver, gallbladder, colorectal cancer.

The uniqueness of the Department of Drug Treatment of Tumors lies in the ability to offer precision drug-based antitumor therapy for patients undergoing hemodialysis or those with concomitant kidney pathology. The department conducts antitumor drug treatment simultaneously with hemodialysis.

It enables precise calculation of the infusion regimen, allowing optimal pharmacokinetics and pharmacodynamics of antitumor drugs to be maintained.

Collaboration with the molecular genetics service provides access to the results of extended biomarker panel testing, facilitating the selection of the most effective antitumor therapy.

Specialized programs for the prevention of alopecia (hair loss) are conducted using innovative devices, along with other supportive care programs aimed at preventing nausea and vomiting, anemia, neutropenia, and other complications.

The Day Hospital of the Drug Treatment of Tumors is a structural unit of the Department of Drug Treatment at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology.

The objective of this unit is to provide high-quality medical treatment for patients with various oncological diseases while minimizing patient stay in the ward. Antitumor therapy is one of the main methods of treatment of oncological diseases, along with surgical treatment and radiation therapy. In recent years, the development of new effective anti-tumor drugs and the improvement of supportive therapy to reduce side effects have allowed patients to be treated on an outpatient basis while maintaining their usual lifestyle. Department «Day hospital of drug treatment of tumors» provides comprehensive medical (non-surgical) services for patients with oncological diseases.

Services include anti-tumor drug therapy in a day hospital, as well as counseling and supportive therapy. The department provides systemic treatment: chemotherapy, immunotherapy, targeted therapy. Oncologists and nurses work together, using their expertise and knowledge to deliver skilled health care. The oncological care phases in the office follow the principle of succession. Oncologist in the process of primary consultation determines the plan of necessary diagnostic, laboratory and molecular-genetic procedures. Based on the results of the examination, an anti-tumor treatment plan is determined.

The type and treatment of the patient’s antitumor therapy will be determined after an interdisciplinary clinical stage.

The treatment of patients with tumors of unknown primary origin is carried out at the Center for Personalized Oncology, based on the Day Hospital at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology.

Tumors of unknown primary origin (TUP) present a unique clinical challenge in modern oncology, requiring a personalized therapeutic approach. The treatment of this patient group is based on a comprehensive analysis of the clinical and morphological characteristics of the tumor and the individual patient’s features.

Managing patients with tumors of unknown primary origin demands a multidisciplinary approach and continuous refinement of antitumor treatment strategies. The integration of advanced molecular diagnostic methods combined with classical clinical and morphological criteria opens new possibilities for personalized treatment and improves survival prognosis for this patient category.

The Medical Tumor Treatment Division is developing:

1. Personalized protocols of drug antitumor therapy based on data from molecular-genetic studies performed using NGS and/or other techniques:
   • for patients with undetected primary localization tumors,
   • for patients with solid tumors resistant to standard drug antitumor therapy, in particular, in cancer: breast, stomach, liver, bile ducts, colon, ovarian cancer, body and cervix.
2. Development of personalized therapeutic protocols for patients:
   • with HBP and on hemodialysis,
   • with impaired kidney function as a result of tumor infiltration of the urinary system.
3. Development of protocols for personalized supportive therapy of cancer patients against the background of therapeutic anti-tumor treatment.
4. Development of a strategy for evaluation of resection disease and dynamic monitoring of cancer patients based on liquid biopsy technologies.
5. Development of a strategy to evaluate the effectiveness of treatment in patients with metastatic solid forms of malignant neoplasms based on the determination of circulating tumor DNA and mutation status dynamics.

Data on clinical trials is being updated, for participation in clinical trials or proposals to conduct a clinical trial please contact e-mail: chemoncouro@gmail.com

To receive treatment in the Day Hospital of the Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology, the patient must:

Obtain a referral for consultation and treatment (if necessary) from the attending physician or apply independently.

Schedule an appointment through the call center: +7 (499) 110-40-67.

Provide the necessary documents for registration: passport, compulsory or voluntary medical insurance policy (OMS or DMS), SNILS (Individual Insurance Account Number), and medical documents with examination results.

Arrive at the appointed time for consultation at the Consultation and Diagnostic Center.

If necessary, undergo additional examinations to clarify the diagnosis and select the optimal therapy.

Appointments and consultations are conducted by prior arrangement. It is recommended to timely clarify all necessary information with the operators of the institution’s contact center.